RP-HPLC raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-08-01 and is reviewed periodically as new material appears.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
Purity is normally reported as a percentage of total peak area, a figure that does not account for water content, residual solvents, or counterions. Trifluoroacetate and acetate are the most frequent counterions in lyophilized peptides, and they shift the true peptide content away from the mass of the powder. A separate quantitative assay is therefore needed to state content accurately. Certificates of analysis often omit these details, which makes batch-to-batch comparison difficult and limits conclusions drawn when results from different suppliers are compared.
Lyophilized material is generally held at minus twenty degrees Celsius or lower, protected from moisture and light. Repeated excursions to room temperature cause condensation inside the vial and gradual moisture uptake, both of which shorten shelf life. Containers should be allowed to equilibrate before opening so that water does not condense on the solid. Dividing a batch into single-use aliquots reduces freeze-thaw cycling. Solid peptide handled this way is usually considered stable for months to years, while the same material in solution degrades on a much shorter timescale.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Value for the free base |
| Molar mass | 711.9 g/mol | Calculated from the formula |
| Appearance | White to off-white powder | Typical lyophilized form |
| Mechanism class | Ghrelin receptor agonist | Also described as a secretagogue |
| Half-life | About 2 hours | Reported for human circulation |
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
Identity and purity are assessed by complementary methods rather than a single test. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and reports a percentage purity. Mass spectrometry, most often with electrospray ionization, confirms the expected molecular mass and detects sequence-related variants. Amino acid analysis can verify composition, while water content and residual counterion measurements support the mass balance of a batch. Stability studies under accelerated conditions are used to estimate shelf life, though such estimates carry uncertainty for long-term storage.
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
Long-term storage of the dry powder is typically at minus twenty degrees Celsius or lower, protected from light and moisture. Solutions are commonly kept frozen and thawed only once, because repeated freeze-thaw cycles can promote aggregation and loss of measurable peptide content. Buffers near neutral pH are preferred over strongly acidic or strongly basic conditions. Shipping at ambient temperature is acceptable for short periods when the powder remains sealed and desiccated.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Quality control for research-grade ipamorelin is not governed by a single harmonized pharmacopeial monograph, so certificates of analysis vary between suppliers. Common tests include appearance, solubility, water content, peptide content by quantitative amino acid analysis, and residual counterion measurement. Independent verification by an outside laboratory is often used to confirm identity and purity claims. Salt form, counterion content, and residual solvent levels are frequently unspecified, which complicates direct comparison between lots and leaves reproducibility partly unresolved.
Identity and purity assessment of ipamorelin relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength where the peptide backbone absorbs. Mass confirmation is typically obtained by electrospray ionization mass spectrometry or by liquid chromatography coupled to mass spectrometry, comparing the observed mass with the calculated value. Amino acid analysis and peptide mapping after enzymatic digestion can confirm the sequence. Impurity profiles include deletion peptides, truncated fragments, and oxidation products, reported as relative area percentages.
Lyophilized ipamorelin is generally held at minus twenty degrees Celsius or colder, protected from light and moisture. In solution the peptide is less stable, and degradation proceeds through hydrolysis of the amide backbone, oxidation of the histidine residue, and aggregation. Repeated freeze-thaw cycles accelerate these processes, so dividing material into single-use aliquots before freezing is common practice in research settings. Buffered formulations near neutral pH tend to show the slowest degradation, while strongly acidic or basic conditions raise hydrolysis rates. Stability data specific to ipamorelin are sparse, and much guidance is extrapolated from other short peptides.
=== High blood pressure === Valsartan and hydrochlorothiazide are both medications indicated as initial therapy for high blood pressure. When high blood pressure is not effectively controlled on a single medication they can be used in a combination.
== Career == Butler began as an instructor of medicine at Yale University (1994–1995) and later served as assistant professor at Vanderbilt University (1999–2006), where he was medical director of both the Heart Transplant and heart-lung transplant programs. In 2007, he joined Emory University as a full professor of medicine and director of the Heart Failure Research Program. At Stony Brook University, Butler served as Director of Cardiovascular Medicine and co-director of the Heart Institute (2014–2017), where he held the Charles A. Gargano Chair in Cardiology. From 2018 to 2022, he chaired the Department of Medicine at the University of Mississippi Medical Center, where he was also a professor of Physiology and Biophysics and held the Patrick H. Lehan Chair in Cardiovascular Research. Butler has combined clinical work with research, education, and leadership, directing heart failure and transplant programs at Vanderbilt and Tennessee Valley Healthcare systems. He served as Deputy Chief Science Officer for the American Heart Association (AHA) from 2009 to 2016. He has chaired committees for the Heart Failure Society of America and the American College of Cardiology, and represented the U.S. on the European Society of Cardiology Heart Failure Guidelines panel. Butler is a Fellow of the AHA, ACC, HFSA, and ESC. Butler chairs the U.S. Food and Drug Administration's Cardio-Renal Advisory Committee, co-chairs the NIH-funded HeartShare study on heart failure progression, and serves as principal investigator for several international cardiovascular trials.
== Methodology == To begin HPTLC, a stationary phase has to be determined to separate different compounds within a mixture. Around 90% of all pharmaceutical separations are performed on normal phase silica gel; however, other stationary phases such as alumina can be used for samples with dissociating compounds and cellulose for ionic compounds. The reverse-phase HPTLC method (similar methodology to reverse-phase TLC) is used for compounds with high polarity. After the selection of the stationary phase, plates are generally washed with methanol and dried in an oven to remove excess solvent. Selection for the mobile phase is one of the most important processes of HPTLC and follows a 'trial and error' pathway. However, the 'PRISMA' system stands as a guideline for finding the optimal mobile phase. The mobile phase is dependent on the absorptivity of the stationary phase and the composition of the compound of interest. The compound is first tested with solutions such as diethyl ether, ethanol, dichloromethane, chloroform for normal phase HPTLC, or solutions such as methanol, acetonitrile, and tetrahydrofuran for reverse phase HPTLC. The retardation factors (Rf) of the compounds with the selected solvent are then analyzed and the solvent that gives the largest Rf is chosen to be the mobile phase for the compound. Then, the mobile solvent strength is tested against hexane (for normal HPTLC) and water (for reverse-phase HPTLC) to determine the need for adjustment.
Paul John Flory (June 19, 1910 – September 9, 1985) was an American chemist and Nobel laureate who was known for his work in the field of polymers, or macromolecules. He was a pioneer in understanding the behavior of polymers in solution, and won the Nobel Prize in Chemistry in 1974 "for his fundamental achievements, both theoretical and experimental, in the physical chemistry of macromolecules".
In his publication, Balard stated that he changed the name from muride to brôme on the proposal of M. Anglada. The name brôme (bromine) derives from the Greek βρῶμος (brômos, "stench"). Other sources claim that the French chemist and physicist Joseph-Louis Gay-Lussac suggested the name brôme for the characteristic smell of the vapours. Bromine was not produced in large quantities until 1858, when the discovery of salt deposits in Stassfurt enabled its production as a by-product of potash. Apart from some minor medical applications, the first commercial use was the daguerreotype. In 1840, bromine was discovered to have some advantages over the previously used iodine vapour to create the light sensitive silver halide layer in daguerreotypy. By 1864, a 25% solution of liquid bromine in .75 molar aqueous potassium bromide was widely used to treat gangrene during the American Civil War, before the publications of Joseph Lister and Pasteur. Potassium bromide and sodium bromide were used as anticonvulsants and sedatives in the late 19th and early 20th centuries, but were gradually superseded by chloral hydrate and then by the barbiturates. In the early years of the First World War, bromine compounds such as xylyl bromide were used as poison gas.
Sources: en.wikipedia.org
Department of Food Science and Nutrition Department of Public Health and Epidemiology Department of Microbiology & Molecular Biology Department of Health Informatics Department of Diagnostic Medical Sonography Department of Clinical Laboratory Sciences Department of Art, Design & Cultural Studies Department of Botany Department of Zoology Department of Chemistry Department of English language & literature Department of Economics Department of Islamic Studies Department of Political Science Department of Psychology Department of Pakistan Studies Department of Urdu Department of Computer Science Department of Statistics Department of Mathematics Department of Law Department of Physics Department of Social Work IT Section
=== Possible health risks === Some evidence suggests that T. molitor may pose a health risk, as humans and animals can consume the eggs and larvae of the beetle with grain-based food. Although they are usually either digested or are excreted with feces, sometimes, they are able to survive and live in the alimentary tract. The first cases of T. molitor larvae in human organs date back to the 19th century, where their presence was observed in the gastrointestinal tract, including the stomach and intestines. There were other cases, such as a reported ulcer infestation of T. molitor in an AIDS patient and a concerned urinary canthariasis in a ten-year-old boy in Iran in 2019, which was the last reported human case of canthariasis caused by T. molitor. However, there are very few reported cases of live larvae in animals, and there are no reports of gastrointestinal canthariasis in farm animals. A study analysing the results of patients in Poland for the presence of specific IgE antibodies to the mealworm was conducted prior to its widespread introduction as a food ingredient. Sensitisation to the mealworm was detected in 4.3% of the patients, with monosensitisation occurring rarely and affecting 0.7% of this group. It was determined that the presence of antibodies to the mealworm most often co-occurs with sensitization to other edible insects, such as the house cricket and the migratory locust, as well as to tropomyosins from shrimp and house dust mites. The primary or cross-sensitization may differ in different populations depending on the dietary habits or geographical zone.
== Contraindications == Bicalutamide is pregnancy category X, or "contraindicated in pregnancy", in the U.S., and pregnancy category D, the second most restricted rating, in Australia. As such, it is contraindicated in women during pregnancy, and women who are sexually active and who can or may become pregnant are strongly recommended to take bicalutamide only in combination with adequate contraception. It is unknown whether bicalutamide is excreted in breast milk, but many drugs are excreted in breast milk, and for this reason, bicalutamide treatment is similarly not recommended while breastfeeding. In individuals with severe, though not mild-to-moderate hepatic impairment, there is evidence that the elimination of bicalutamide is slowed, and hence, caution may be warranted in these patients as circulating levels of bicalutamide may be increased. In severe hepatic impairment, the elimination half-life of the active (R)-enantiomer of bicalutamide is increased by about 1.75-fold (76% increase; elimination half-life of 5.9 and 10.4 days for normal and impaired patients, respectively). The elimination half-life of bicalutamide is unchanged in renal impairment.
On 7 January 2024, Los Choneros leader José Adolfo Macías Villamar escaped from prison in the city of Guayaquil, on the day of his scheduled transfer to a maximum-security prison. The events were reported the next day by authorities, with charges being filed against two prison guards. Following the escape, Noboa declared a state of emergency, to last for 60 days, giving authorities the power to suspend people's rights and allowing the military to be mobilized inside prisons. Riots ensued in multiple prisons across Ecuador.
=== Health Services division === UPMC's Provider Services consists of an array of clinical capabilities that includes hospitals, specialty service lines (including transplantation, behavioral health, cancer care, children's health, women's health, and rehabilitation services among other centers, institutes, and services), contract services (emergency medicine, pharmacy, and laboratory), supporting foundations, captive insurance programs, and approximately 3,600 employed physicians with associated practices. Hospital activity is categorized in four distinct groups: 1. academic hospitals that provide comprehensive clinical services and specialty services and that are the primary academic and teaching centers; 2. community hospitals that provide core clinical services to suburban populations; 3. regional hospitals that provide clinical core services to broader areas of the Western Pennsylvania region; and 4. pre- and post-acute care capabilities that include a network of home health services (UPMC HomeCare) and a network of 15 senior living facilities (UPMC Senior Communities).
Sources: en.wikipedia.org
=== 1,2-Diols === The 1,2‑diols (glycols) present for protecting-group chemistry a special class of alcohols. One can exploit the adjacency of two hydroxy groups, e.g. in sugars, in that one protects both hydroxy groups codependently as an acetal. Common in this situation are the benzylidene, isopropylidene and cyclohexylidene or cyclopentylidene acetals.
Glycine MS Spectrum Glycine Glycine cleavage system Glycine Therapy – A New Direction for Schizophrenia Treatment? ChemSub Online (Glycine). NASA scientists have discovered glycine, a fundamental building block of life, in samples of comet Wild 2 returned by NASA's Stardust spacecraft.
In anatomy, the interstitium is a contiguous fluid-filled space existing between a structural barrier, such as a cell membrane or the skin, and internal structures, such as organs, including muscles and the circulatory system. Fluid in this space – the interstitial fluid – is composed of solutes and water draining into the lymphatic system. The interstitial compartment is composed of connective tissues comprising an extracellular matrix, which is situated outside the blood, lymphatic vessels, and the parenchyma of organs. The interstitium has a role in regulating solute concentration, protein transport, and hydrostatic pressure, which may affect human pathology and physiological responses, such as edema, inflammation, and shock.
=== Classical-like === Classical-like EDS (clEDS) is characterized by skin hyperextensibility with velvety skin texture and no presence of atrophic scarring, generalized joint hypermobility with or without recurrent dislocations (most often shoulder and ankle), and easily bruised skin or spontaneous ecchymoses (discolorations of the skin resulting from bleeding underneath). It can be caused by autosomal recessive variations in the TNXB gene.
Preliminary 2021 calculations predicted that flerovium should have melting point −73 °C (lower than mercury at −39 °C and copernicium, predicted 10 ± 11 °C) and boiling point 107 °C, which would make it a liquid metal. Like mercury, radon, and copernicium, but not lead and oganesson (eka-radon), flerovium is calculated to have no electron affinity. A 2010 study published calculations predicting a hexagonal close-packed crystal structure for flerovium due to spin–orbit coupling effects, and a density of 9.928 g/cm3, though this was noted to be probably slightly too low. Newer calculations published in 2017 expected flerovium to crystallize in face-centred cubic crystal structure like its lighter congener lead, and calculations published in 2022 predicted a density of 11.4 ± 0.3 g/cm3, similar to lead (11.34 g/cm3). These calculations found that the face-centred cubic and hexagonal close-packed structures should have nearly the same energy, a phenomenon reminiscent of the noble gases. These calculations predict that hexagonal close-packed flerovium should be a semiconductor, with a band gap of 0.8 ± 0.3 eV. (Copernicium is also predicted to be a semiconductor.) These calculations predict that the cohesive energy of flerovium should be around −0.5 ± 0.1 eV; this is similar to that predicted for oganesson (−0.45 eV), larger than that predicted for copernicium (−0.38 eV), but smaller than that of mercury (−0.79 eV).
Sources: en.wikipedia.org
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.
It binds the ghrelin receptor, known as the growth hormone secretagogue receptor type 1a. Activation of that receptor triggers signaling that leads to growth hormone release. Selectivity for growth hormone over cortisol and prolactin is the property most often cited for this compound.
Published estimates place the circulating half-life at roughly two hours in humans. Clearance involves peptidase activity and renal handling. Because the peptide is short-lived, release patterns after administration are usually described as pulsatile rather than sustained.
It is reported as the percentage of total peak area in a reversed-phase chromatogram. That number does not reflect water content, residual solvents, or counterions. The actual peptide content is therefore lower than the stated purity figure suggests.